Apolipoprotein M: Research progress, regulation and metabolic functions (Review)

Huang,Li‑Zhu; Gao,Jia‑Lin; Pu,Chun; Zhang,Pu‑Hong; Wang,Li‑Zhuo; Feng,Gang; Zhang,Yao

doi:10.3892/mmr.2015.3658

Apolipoprotein M: Research progress, regulation and metabolic functions (Review)

Authors:
- Li‑Zhu Huang
- Jia‑Lin Gao
- Chun Pu
- Pu‑Hong Zhang
- Li‑Zhuo Wang
- Gang Feng
- Yao Zhang
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, Wannan Medical College, Wuhu, Anhui 241001, P.R. China, Department of Endocrinology and Genetic Metabolism, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui 241002, P.R. China
Published online on: April 22, 2015 https://doi.org/10.3892/mmr.2015.3658
Pages: 1617-1624

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Apolipoprotein M (ApoM) is a novel lipoprotein-associated plasma protein of the apolipoprotein family. It is predominantly enriched in high‑density lipoprotein (HDL), and is also present in small quantities in low‑density lipoprotein (LDL) and in very low‑density lipoprotein. Transgenic animal experiments have suggested that ApoM can be transformed into various lipoproteins and may be involved in lipoprotein metabolism. ApoM has five subtypes, however, their biological functions remain to be elucidated. The α‑helix, formed by ApoM through hydrophobic signal peptides, is anchored to the phospholipid monomolecular layers of HDL. Hydrophobic domains can associate with small lipophilic ligands and perform biological functions. ApoM may affect HDL metabolism and exhibit anti‑atherosclerotic functions. Human HDL, containing ApoM subfractions, can protect LDL from oxidation and regulate cholesterol efflux more effectively than HDL without ApoM. Therefore, it is highly correlated with plasma cholesterol levels in the human body. Although previous studies have reported no difference in ApoM between groups of patients with coronary heart disease (CHD) and a normal control groups, the anti‑atherosclerotic effect of ApoM is evident. ApoM is highly expressed in renal proximal tubule cells and is secreted into the urine in tubule cells. However, it is usually reabsorbed by giantin‑associated proteins in a process, which is also affected in kidney disease. In addition to liver and kidney cells, low expression levels of ApoM occur in the intestinal tract and are associated with lymph node metastasis of colorectal cancer. ApoM gene polymorphism is associated with CHD, diabetes and other immune‑associated diseases. Investigations into the gene regulation of ApoM may assist in further clarifying the role of ApoM in blood glucose and lipid metabolism. Genetic modification of the mouse ApoM gene is an essential technique to investigate the gene expression and regulation of ApoM, and to clarify the potential roles of ApoM in lipoprotein metabolism, atherosclerosis, diabetes and renal diseases.

View Figures

View References

1	Xu N and Dahlbäck B: A novel human apolipoprotein (apoM). J Biol Chem. 274:31286–31290. 1999. View Article : Google Scholar : PubMed/NCBI
2	Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH and Dahlbäck B: Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res. 47:1833–1843. 2006. View Article : Google Scholar : PubMed/NCBI
3	Axler O, Ahnström J and Dahlbäck B: An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J Lipid Res. 48:1772–1780. 2007. View Article : Google Scholar : PubMed/NCBI
4	Zhang XY, Dong X, Zheng L, et al: Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. Acta Histochem. 105:67–72. 2003. View Article : Google Scholar : PubMed/NCBI
5	Zhang XY, Jiao GQ, Hurtig M, et al: Expression pattern of apolipoprotein M during mouse and human embryogenesis. Acta Histochem. 106:123–128. 2004. View Article : Google Scholar : PubMed/NCBI
6	Faber K, Axler O, Dahlbäck B and Nielsen LB: Characterization of apoM in normal and genetically modified mice. J Lipid Res. 45:1272–1278. 2004. View Article : Google Scholar : PubMed/NCBI
7	Flower DR, North AC and Attwood TK: Structure and sequence relationships in the lipocalins and related proteins. Protein Sci. 2:753–761. 1993. View Article : Google Scholar : PubMed/NCBI
8	Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S and La Du BN: Human serum Paraoxonase/Arylesterase’s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol. 19:2214–2225. 1999. View Article : Google Scholar : PubMed/NCBI
9	Axler O, Ahnström J and Dahlbäck B: Apolipoprotein M associates to lipoproteins through its retained signal peptide. FEBS Lett. 582:826–828. 2008. View Article : Google Scholar : PubMed/NCBI
10	Duan J, Dahlbäck B and Villoutreix BO: Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis. FEBS Lett. 499:127–132. 2001. View Article : Google Scholar
11	Christoffersen C, Ahnström J, Axler O, Christensen EI, Dahlbäck B and Nielsen LB: The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma. J Biol Chem. 283:18765–18772. 2008. View Article : Google Scholar : PubMed/NCBI
12	Flower DR, North AC and Sansom CE: The lipocalin protein family: structural and sequence overview. Biochim Biophys Acta. 1482:9–24. 2000. View Article : Google Scholar : PubMed/NCBI
13	Sevvana M, Ahnström J, Egerer-Sieber C, Lange HA, Dahlbäck B and Muller YA: Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M. J Mol Biol. 393:920–936. 2009. View Article : Google Scholar : PubMed/NCBI
14	Ahnström J, Faber K, Axler O and Dahlbäck B: Hydrophobic ligand binding properties of the human lipocalin apolipoprotein M. J Lipid Res. 48:1754–1762. 2007. View Article : Google Scholar : PubMed/NCBI
15	Christoffersen C, Obinata H, Kumaraswamy SB, et al: Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA. 108:9613–9618. 2011. View Article : Google Scholar : PubMed/NCBI
16	Faber K, Hvidberg V, Moestrup SK, Dahlbäck B and Nielsen LB: Megalin is a receptor for apolipoprotein M and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M. Mol Endocrinol. 20:212–218. 2006. View Article : Google Scholar
17	Karlsson H, Lindqvist H, Tagesson C and Lindahl M: Characterization of apolipoprotein M isoforms in low-density lipoprotein. J Proteome Res. 5:2685–2690. 2006. View Article : Google Scholar : PubMed/NCBI
18	Tetaz T, Detzner S, Friedlein A, Molitor B and Mary JL: Hydrophilic interaction chromatography of intact, soluble proteins. J Chromatogr A. 1218:5892–5896. 2011. View Article : Google Scholar
19	Xu N, Zhang XY, Dong X, Ekström U, Ye Q and Nilsson-Ehle P: Effects of platelet-activating factor, tumor necrosis factor and interleukin-1alpha on the expression of apolipoprotein M in HepG2 cells. Biochem Biophys Res Commun. 292:944–950. 2002. View Article : Google Scholar : PubMed/NCBI
20	Xu N, Hurtig M, Zhang XY, Ye Q and Nilsson-Ehle P: Transforming growth factor-beta down-regulates apolipoprotein M in HepG2 cells. Biochim Biophys Acta. 1683:33–37. 2004. View Article : Google Scholar : PubMed/NCBI
21	Swenson ES, Guest I, Ilic Z, et al: Hepatocyte nuclear factor-1 as marker of epithelial phenotype reveals marrow-derived hepatocytes, but not duct cells, after liver injury in mice. Stem Cells. 26:1768–1777. 2008. View Article : Google Scholar : PubMed/NCBI
22	Richter S, Shih DQ, Pearson ER, et al: Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes. 52:2989–2995. 2003. View Article : Google Scholar : PubMed/NCBI
23	Shih DQ, Bussen M, Sehayek E, et al: Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet. 27:375–382. 2001. View Article : Google Scholar : PubMed/NCBI
24	Mosialou I, Krasagakis K and Kardassis D: Opposite regulation of the human apolipoprotein M gene by hepatocyte nuclear factor 1 and Jun transcription factors. J Biol Chem. 286:17259–17269. 2011. View Article : Google Scholar : PubMed/NCBI
25	Venteclef N, Haroniti A, Tousaint JJ, Talianidis I and Delerive P: Regulation of anti-atherogenic apolipoprotein M gene expression by the orphan nuclear receptor LRH-1. J Biol Chem. 283:3694–3701. 2008. View Article : Google Scholar
26	Zhang Y and Mangelsdorf DJ: LuXuRies of lipid homeostasis: the unity of nuclear hormone receptors, transcription regulation, and cholesterol sensing. Mol Interv. 2:78–87. 2002. View Article : Google Scholar
27	Zhang Y, Chen CJ, Yang QL, Cheng LQ, Wang H and Huang LZ: Effect of interfering hepatocyte nuclear factor-1 alfa in HepG2 on the expressions of apoM, apoA-I and the correlative key enzyme of cholesterol metabolism. Zhonghua Gan Zang Bing Za Zhi. 19:121–126. 2011.In Chinese. PubMed/NCBI
28	Calayir E, Becker TM, Kratzer A, et al: LXR-agonists regulate ApoM expression differentially in liver and intestine. Curr Pharm Biotechnol. 9:516–521. 2008. View Article : Google Scholar : PubMed/NCBI
29	Fielding CJ and Fielding PE: Cellular cholesterol efflux. Biochim Biophys Acta. 1533:175–189. 2001. View Article : Google Scholar : PubMed/NCBI
30	Di D, Wang Z, Liu Y, et al: ABCA1 upregulating apolipoproein M expression mediates via the RXR/lXR pathway in HepG2 cells. Biochem Biophys Res Commun. 421:152–156. 2012. View Article : Google Scholar : PubMed/NCBI
31	Zhang X, Zhu Z, Luo G, Zheng L, Nilsson-Ehle P and Xu N: Liver X receptor agonist downregulates hepatic apoM expression in vivo and in vitro. Biochem Biophys Res Commun. 371:114–117. 2008. View Article : Google Scholar : PubMed/NCBI
32	Mosialou I, Zannis VI and Kardassis D: Regulation of human apolipoprotein m gene expression by orphan and ligand-dependent nuclear receptors. J Biol Chem. 285:30719–30730. 2010. View Article : Google Scholar : PubMed/NCBI
33	Yi-Zhou Y, Guo Qing J, Jian Z, et al: Dihydrotestosterone regulating apolipoprotein M expression mediates via protein kinase C in HepG2 cells. Lipids Health Dis. 11:1682012. View Article : Google Scholar : PubMed/NCBI
34	Silver DL, Jiang XC, Arai T, Bruce C and Tall AR: Receptors and lipid transfer proteins in HDL metabolism. Ann NY Acad Sci. 902:103–111. 2000. View Article : Google Scholar : PubMed/NCBI
35	Stein O and Stein Y: Atheroprotective mechanisms of HDL. Atherosclerosis. 144:285–301. 1999. View Article : Google Scholar : PubMed/NCBI
36	Assmann G and Nofer JR: Atheroprotective effects of high-density lipoproteins. Annu Rev Med. 54:321–341. 2003. View Article : Google Scholar
37	Phillips MC, Gillotte KL, Haynes MP, Johnson WJ, Lund-Katz S and Rothblat GH: Mechanisms of high density lipoprotein-mediated efflux of cholesterol from cell plasma membranes. Atherosclerosis. 137(Suppl): 13–17. 1998. View Article : Google Scholar
38	Santamarina-Fojo S, Lambert G, Hoeg JM and Brewer HB Jr: Lecithin-cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol. 11:267–275. 2000. View Article : Google Scholar : PubMed/NCBI
39	Sparks DL and Pritchard PH: Transfer of cholesteryl ester into high density lipoprotein by cholesteryl ester transfer protein: effect of HDL lipid and apoprotein content. J Lipid Res. 30:1491–1498. 1989.PubMed/NCBI
40	Christoffersen C, Pedersen TX, Gordts PL, Roebroek AJ, Dahlbäck B and Nielsen LB: Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis. Circ Res. 106:1624–1634. 2010. View Article : Google Scholar : PubMed/NCBI
41	Christoffersen C, Jauhiainen M, Moser M, et al: Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem. 283:1839–1847. 2008. View Article : Google Scholar
42	Wolfrum C, Poy MN and Stoffel M: Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med. 11:418–422. 2005. View Article : Google Scholar : PubMed/NCBI
43	Ahnström J, Axler O, Jauhiainen M, et al: Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies. J Lipid Res. 49:1912–1917. 2008. View Article : Google Scholar : PubMed/NCBI
44	Rye KA, Duong M, Psaltis MK, et al: Evidence that phospholipids play a key role in pre-beta apoA-I formation and high-density lipoprotein remodeling. Biochemistry. 41:12538–12545. 2002. View Article : Google Scholar : PubMed/NCBI
45	Christoffersen C, Jauhiainen M, Moser M, et al: Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem. 283:1839–1847. 2008. View Article : Google Scholar
46	Elsøe S, Ahnström J, Christoffersen C, et al: Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. Atherosclerosis. 221:91–97. 2012. View Article : Google Scholar
47	Elsøe S, Christoffersen C, Luchoomun J, Turner S and Nielsen LB: Apolipoprotein M promotes mobilization of cellular cholesterol in vivo. Biochim Biophys Acta. 1831:1287–1292. 2013. View Article : Google Scholar : PubMed/NCBI
48	Huang XS, Zhao SP, Hu M and Luo YP: Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation. Med Hypotheses. 69:136–140. 2007. View Article : Google Scholar : PubMed/NCBI
49	Christoffersen C and Nielsen LB: Apolipoprotein M-a new biomarker in sepsis. Crit Care. 16:1262012. View Article : Google Scholar
50	Kumaraswamy SB, Linder A, Akesson P and Dahlbäck B: Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes. Crit Care. 16:R602012. View Article : Google Scholar : PubMed/NCBI
51	Sattler KJ, Elbasan S, Keul P, et al: Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol. 105:821–832. 2010. View Article : Google Scholar : PubMed/NCBI
52	Arkensteijn BW, Berbée JF, Rensen PC, Nielsen LB and Christoffersen C: The apolipoprotein m-sphin-gosine-1-phosphate axis: biological relevance in lipoprotein metabolism, lipid disorders and atherosclerosis. Int J Mol Sci. 14:4419–4431. 2013. View Article : Google Scholar : PubMed/NCBI
53	Kurano M, Tsukamoto K, Ohkawa R, et al: Liver involvement in sphingosine 1-phosphate dynamism revealed by adenoviral hepatic overexpression of apolipoprotein M. Atherosclerosis. 229:102–109. 2013. View Article : Google Scholar : PubMed/NCBI
54	Xu WW, Zhang Y, Tang YB, et al: A genetic variant of apolipoprotein M increases susceptibility to coronary artery disease in a Chinese population. Clin Exp Pharmacol Physiol. 35:546–551. 2008. View Article : Google Scholar
55	Jiao GQ, Yuan ZX, Xue YS, et al: A prospective evaluation of apolipoprotein M gene T-778C polymorphism in relation to coronary artery disease in Han Chinese. Clin Biochem. 40:1108–1112. 2007. View Article : Google Scholar : PubMed/NCBI
56	Zhang Z, Chu G and Yin RX: Apolipoprotein M T-778C polymorphism is associated with serum lipid levels and the risk of coronary artery disease in the Chinese population: a meta-analysis. Lipids Health Dis. 12:1352013. View Article : Google Scholar : PubMed/NCBI
57	Brorsson C, Hansen NT, Lage K, Bergholdt R, Brunak S and Pociot F; Diabetes Genetics Consortium: Identification of T1D susceptibility genes within the MHC region by combining protein interaction networks and SNP genotyping data. Diabetes Obes Metab. 11(Suppl 1): 60–66. 2009. View Article : Google Scholar : PubMed/NCBI
58	Wu X, Niu N, Brismar K, et al: Apolipoprotein M promoter polymorphisms alter promoter activity and confer the susceptibility to the development of type 1 diabetes. Clin Biochem. 42:17–21. 2009. View Article : Google Scholar
59	Zhou JW, Tsui SK, Ng MC, et al: Apolipoprotein M gene (APOM) polymorphism modifies metabolic and disease traits in type 2 diabetes. PLoS One. 6:e173242011. View Article : Google Scholar : PubMed/NCBI
60	Zhang YY, Proenca R, Margherita M, et al: Positional cloning of the mouse obese gene and its human homologue. Nature. 372:425–432. 1994. View Article : Google Scholar : PubMed/NCBI
61	Ahima RS and Flier JS: Leptin. Annu Rev Physiol. 62:413–437. 2000. View Article : Google Scholar : PubMed/NCBI
62	Xu N, Nilsson-Ehle P and Ahrén B: Correlation of apolipoprotein M with leptin and cholesterol in normal and obese subjects. J Nutr Biochem. 15:579–582. 2004. View Article : Google Scholar : PubMed/NCBI
63	Xu N, Nilsson-Ehle P, Hurtig M and Ahrén B: Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo. Biochem Biophys Res Commun. 321:916–921. 2004. View Article : Google Scholar : PubMed/NCBI
64	Luo G, Hurtig M, Zhang X, Nilsson-Ehle P and Xu N: Leptin inhibits apolipoprotein M transcription and secretion in human hepatoma cell line, HepG2 cells. Biochim Biophys Acta. 1734:198–202. 2005. View Article : Google Scholar : PubMed/NCBI
65	Ooi EM, Watts GF, Chan DC, et al: Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men. Atherosclerosis. 210:326–330. 2010. View Article : Google Scholar
66	Kappelle PJ, Lambert G, Dahlbäck B, Nielsen LB and Dullaart RP: Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects. Atherosclerosis. 214:492–494. 2011. View Article : Google Scholar
67	Cervin C, Axler O, Holmkvist J, et al: An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA. J Intern Med. 267:316–321. 2010. View Article : Google Scholar
68	Mughal SA, Park R, Nowak N, et al: Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes. Diabet Med. 30:246–250. 2013. View Article : Google Scholar
69	Xu N, Nilsson-Ehle P and Ahrén B: Suppression of apolipoprotein M expression and secretion in alloxan-diabetic mouse: Partial reversal by insulin. Biochem Biophys Res Commun. 342:1174–1177. 2006. View Article : Google Scholar : PubMed/NCBI
70	Zhang X, Jiang B, Luo G, Nilsson-Ehle P and Xu N: Hyperglycemia down-regulates apolipoprotein M expression in vivo and in vitro. Biochim Biophys Acta. 1771:879–882. 2007. View Article : Google Scholar : PubMed/NCBI
71	Xu N, Ahrén B, Jiang J and Nilsson-Ehle P: Down-regulation of apolipoprotein M expression is mediated by phosphatidylinositol 3-kinase in HepG2 cells. Biochim Biophys Acta. 1761:256–260. 2006. View Article : Google Scholar : PubMed/NCBI
72	Wolfrum C, Howell JJ, Ndungo E and Stoffel M: Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M. J Biol Chem. 283:16940–16949. 2008. View Article : Google Scholar : PubMed/NCBI
73	Luo G, Zhang X, Mu Q, et al: Expression and localization of apolipoprotein M in human colorectal tissues. Lipids Health Dis. 9:1022010. View Article : Google Scholar : PubMed/NCBI
74	Gu JG, Zhu CL, Cheng DZ, Xie Y, Liu F and Zhou X: Enchanced levels of apolipoprotein M during HBV infection feedback suppresses HBV replication. Lipids Health Dis. 10:1542011. View Article : Google Scholar : PubMed/NCBI
75	Jiang J, Wu C, Luo G, et al: Expression of apolipoprotein M in human hepatocellular carcinoma tissues. Acta Histochem. 113:53–57. 2011. View Article : Google Scholar
76	Xu X, Ye Q, Xu N, et al: Effects of ischemia-reperfusion injury on apolipoprotein M expression in the liver. Transplant Proc. 38:2769–2773. 2006. View Article : Google Scholar : PubMed/NCBI
77	Park YJ, Yoo SA, Lee JH, Chung YJ, Cho CS and Kim W: The APOM polymorphism as a novel risk factor for dyslipidaemia in rheumatoid arthritis: a possible shared link between disease susceptibility and dyslipidaemia. Clin Exp Rheumatol. 31:180–188. 2013.
78	Zhao DX, He ZY, Qin X, et al: Association of apolipoprotein M gene polymorphisms with ischemic stroke in a Han Chinese population. J Mol Neurosci. 43:370–375. 2011. View Article : Google Scholar
79	Burkart KM, Manichaikul A, Wilk JB, et al: APOM and high-density lipoprotein cholesterol are associated with lung function and per cent emphysema. Eur Respir J. 43:1003–1017. 2014. View Article : Google Scholar :
80	Kim J, Lee S, In K, et al: Increase in serum haptoglobin and apolipoprotein M in patients with obstructive sleep apnoea. J Sleep Res. 18:313–320. 2009. View Article : Google Scholar : PubMed/NCBI
81	Dullaart RP, Plomgaard P, de Vries R, Dahlbäck B and Nielsen LB: Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness. Clin Chim Acta. 406:129–133. 2009. View Article : Google Scholar : PubMed/NCBI
82	Ahnström J, Gottsäter A, Lindblad B and Dahlbäck B: Plasma concentrations of apolipoproteins A-I, B and M in patients with abdominal aortic aneurysms. Clin Biochem. 43:407–410. 2010. View Article : Google Scholar
83	Ahnström J, Gottsater A, Lindblad B and Dahlbäck B: Plasma concentrations of apolipoproteins A-I, B and M in patients with critical limb ischemia. Clin Biochem. 43:599–603. 2010. View Article : Google Scholar